Integrated genomic sequencing in myeloid blast crisis chronic myeloid leukemia (MBC-CML), identified potentially important findings in the context of leukemogenesis model.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 07 2022
27 07 2022
Historique:
received:
14
03
2022
accepted:
21
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
30
7
2022
Statut:
epublish
Résumé
Chronic myeloid leukemia (CML) is a model of leukemogenesis in which the exact molecular mechanisms underlying blast crisis still remained unexplored. The current study identified multiple common and rare important findings in myeloid blast crisis CML (MBC-CML) using integrated genomic sequencing, covering all classes of genes implicated in the leukemogenesis model. Integrated genomic sequencing via Whole Exome Sequencing (WES), Chromosome-seq and RNA-sequencing were conducted on the peripheral blood samples of three CML patients in the myeloid blast crisis. An in-house filtering pipeline was applied to assess important variants in cancer-related genes. Standard variant interpretation guidelines were used for the interpretation of potentially important findings (PIFs) and potentially actionable findings (PAFs). Single nucleotide variation (SNV) and small InDel analysis by WES detected sixteen PIFs affecting all five known classes of leukemogenic genes in myeloid malignancies including signaling pathway components (ABL1, PIK3CB, PTPN11), transcription factors (GATA2, PHF6, IKZF1, WT1), epigenetic regulators (ASXL1), tumor suppressor and DNA repair genes (BRCA2, ATM, CHEK2) and components of spliceosome (PRPF8). These variants affect genes involved in leukemia stem cell proliferation, self-renewal, and differentiation. Both patients No.1 and No.2 had actionable known missense variants on ABL1 (p.Y272H, p.F359V) and frameshift variants on ASXL1 (p.A627Gfs*8, p.G646Wfs*12). The GATA2-L359S in patient No.1, PTPN11-G503V and IKZF1-R208Q variants in the patient No.3 were also PAFs. RNA-sequencing was used to confirm all of the identified variants. In the patient No. 3, chromosome sequencing revealed multiple pathogenic deletions in the short and long arms of chromosome 7, affecting at least three critical leukemogenic genes (IKZF1, EZH2, and CUX1). The large deletion discovered on the short arm of chromosome 17 in patient No. 2 resulted in the deletion of TP53 gene as well. Integrated genomic sequencing combined with RNA-sequencing can successfully discover and confirm a wide range of variants, from SNVs to CNVs. This strategy may be an effective method for identifying actionable findings and understanding the pathophysiological mechanisms underlying MBC-CML, as well as providing further insights into the genetic basis of MBC-CML and its management in the future.
Identifiants
pubmed: 35896598
doi: 10.1038/s41598-022-17232-w
pii: 10.1038/s41598-022-17232-w
pmc: PMC9329277
doi:
Substances chimiques
RNA
63231-63-0
Fusion Proteins, bcr-abl
EC 2.7.10.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12816Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Hum Mutat. 2011 Oct;32(10):1137-43
pubmed: 21681852
Nat Biotechnol. 2019 Nov;37(11):1351-1360
pubmed: 31570899
Cold Spring Harb Perspect Biol. 2015 Apr 01;7(4):a016600
pubmed: 25833843
Clin Adv Hematol Oncol. 2019 Aug;17(8):447-454
pubmed: 31449513
Nat Biotechnol. 2018 Jan 10;36(1):46-60
pubmed: 29319699
Blood. 2010 Jul 1;115(26):5428-9
pubmed: 20595523
Drug Des Devel Ther. 2019 Mar 08;13:825-843
pubmed: 30880916
Biologics. 2007 Dec;1(4):433-48
pubmed: 19707313
Cancers (Basel). 2021 Jul 17;13(14):
pubmed: 34298798
Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51
pubmed: 28881915
World J Stem Cells. 2019 Aug 26;11(8):476-490
pubmed: 31523368
Genes (Basel). 2021 May 30;12(6):
pubmed: 34070860
Nature. 2017 Aug 17;548(7667):297-303
pubmed: 28783718
Mol Cancer. 2019 Feb 19;18(1):26
pubmed: 30782187
Jpn J Cancer Res. 1998 Aug;89(8):821-4
pubmed: 9765617
Leukemia. 2009 Apr;23(4):656-63
pubmed: 19151774
Science. 2019 Feb 15;363(6428):710-714
pubmed: 30705154
Blood. 2020 Jun 25;135(26):2337-2353
pubmed: 32157296
Signal Transduct Target Ther. 2017 Dec 22;2:17063
pubmed: 29279775
Leukemia. 2011 Mar;25(3):557-60
pubmed: 21274004
Leuk Lymphoma. 1995 Oct;19(3-4):213-21
pubmed: 8535212
Clin Cancer Res. 2017 May 1;23(9):2136-2142
pubmed: 28087641
Blood. 2018 Aug 30;132(9):948-961
pubmed: 29967129
Hemasphere. 2020 Sep 30;4(5):e468
pubmed: 33134861
Genes (Basel). 2020 Jul 06;11(7):
pubmed: 32640569
Leukemia. 2007 May;21(5):868-76
pubmed: 17361230
J Hematol Oncol. 2014 Apr 22;7:36
pubmed: 24754962
J Hematol Oncol. 2019 Dec 5;12(1):131
pubmed: 31801582
DNA Repair (Amst). 2013 Jul;12(7):500-7
pubmed: 23694754
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Stem Cells Int. 2017;2017:5619472
pubmed: 28473858
Leuk Lymphoma. 2021 Sep;62(9):2064-2078
pubmed: 33944660
Genes Cancer. 2012 May;3(5-6):436-46
pubmed: 23226581
J Hematol Oncol. 2020 Oct 20;13(1):140
pubmed: 33081843
Lancet. 2015 Apr 11;385(9976):1447-59
pubmed: 25484026
Front Oncol. 2019 Oct 25;9:1132
pubmed: 31709190
J Clin Invest. 2010 Jul;120(7):2254-64
pubmed: 20592475
Nucleic Acids Res. 2012 May;40(10):4483-95
pubmed: 22319212
BMC Cancer. 2012 Jul 23;12:304
pubmed: 22823977
Nat Commun. 2018 Jan 10;9(1):144
pubmed: 29321523
Haematologica. 2018 Aug;103(8):1278-1287
pubmed: 29724903